Patents Assigned to Mallinckrodt
-
Publication number: 20200163989Abstract: Described are methods and systems for delivering a pharmaceutical gas to a patient.Type: ApplicationFiled: February 3, 2020Publication date: May 28, 2020Applicant: Mallinckrodt Hospital Products IP LimitedInventors: Frederick J. Montgomery, Duncan P. Bathe
-
Patent number: 10661045Abstract: A nitric oxide delivery device including a valve assembly, a control module and a gas delivery mechanism is described. An exemplary gas delivery device includes a valve assembly with a valve and circuit including a memory, a processor and a transceiver in communication with the memory. The memory may include gas data such as gas identification, gas expiration and gas concentration. The transceiver on the circuit of the valve assembly may send wireless optical line-of-sight signals to communicate the gas data to a control module. Exemplary gas delivery mechanisms include a ventilator and a breathing circuit. Methods of administering gases containing nitric oxide are also described.Type: GrantFiled: July 7, 2016Date of Patent: May 26, 2020Assignee: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITEDInventors: Duncan P. Bathe, John Klaus, David Christensen
-
Patent number: 10662209Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.Type: GrantFiled: March 11, 2019Date of Patent: May 26, 2020Assignee: Mallinckrodt Hospital Products IP LimitedInventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
-
Patent number: 10641415Abstract: The current disclosure presents embodiments directed to, among others, a support and/or clamp (60) for receiving a cylindrical element (e.g., a bearing (90)), which can include a base (62), a pair of opposed receiving members (64) projecting from the base (62) and spaced apart from one other to establish a receiving area (66) configured with a size and shape to removably receive at least one of a circular, cylindrical and spherical object therein, and at least one of a detent (24) and magnet (40) arranged within at least a portion of the receiving area (66), the detent (24) and/or magnet (40) configured to at least one of temporarily retain the object within the receiving area (66) and establish a sound associated with the receiving of the object.Type: GrantFiled: May 5, 2016Date of Patent: May 5, 2020Assignee: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITEDInventors: Mark Vandlik, Shaun Wall, Josef Gabelberger, Eric Rabeno
-
Patent number: 10613103Abstract: Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD). Methods for treating premature infants identified as at risk and/or likely to benefit are provided. also provided are methods for identifying premature infants that are not at risk for developing bronchopulmonary dysplasia and/or unlikely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia, and methods for avoiding risks of toxicity and undesirable side effects associated with inhaled nitric oxide therapy comprising administering only non-iNO treatment modalities to these infants.Type: GrantFiled: June 18, 2015Date of Patent: April 7, 2020Assignee: Mallinckrodt Hospital Products IP LimitedInventors: Douglas Stuart Greene, Joseph J. Medicis, Jim Potenziano
-
Patent number: 10604488Abstract: The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.Type: GrantFiled: September 2, 2016Date of Patent: March 31, 2020Assignee: Mallinckrodt LLCInventors: Bobby N. Trawick, David W. Berberich, Christopher W. Grote
-
Publication number: 20200079785Abstract: The present invention provides MMC prodrug compounds and liposomal MMC prodrugs and compositions thereof for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid and a MMC prodrug. The present invention also provides liposomal compositions for the treatment of cancer comprising administering to a patient in need thereof a liposome, wherein the liposome comprises: a phosphatidylcholine lipid; a sterol; a PEG-lipid and a MMC prodrug or a pharmaceutically-acceptable salt thereof.Type: ApplicationFiled: November 8, 2017Publication date: March 12, 2020Applicant: Mallinckrodt LLCInventors: William McGHEE, Michelle SCHMIDT, Margaret GRAPPERHAUS, Kah Tiong KUAN
-
Patent number: 10576225Abstract: Therapy gas delivery systems that provide run-time-to-empty information to a user of the system and methods for administering therapeutic gas to a patient. The therapeutic gas delivery system may include a gas pressure sensor attachable to a therapeutic gas source that communicates therapeutic gas pressure data to a therapeutic gas delivery system controller, a gas temperature sensor positioned to measure gas temperature in the therapeutic gas source that communicates therapeutic gas temperature data to the therapeutic gas delivery system controller, at least one flow controller that communicates therapeutic gas flow rate data to the therapeutic gas delivery system controller, at least one flow sensor that communicates flow rate data to the therapeutic gas delivery system controller, and at least one display that communicates run-time-to-empty to a user of the therapeutic gas delivery system.Type: GrantFiled: May 11, 2015Date of Patent: March 3, 2020Assignee: Mallinckrodt Hospital Products IP LimitedInventors: Jaron M. Acker, Jeff Milsap, Robin Roehl, Jeffrey Schmidt, Craig R. Tolmie
-
Patent number: 10562956Abstract: The present invention relates to nucleotide sequences encoding a fibrinogen alpha, beta or gamma chain. The sequences are optimized for expression in a eukaryotic cell culture system. Such optimized nucleotide sequences allow for the efficient expression of recombinant fibrinogen and variants thereof in intact form in a eukaryotic cell culture system.Type: GrantFiled: October 24, 2016Date of Patent: February 18, 2020Assignee: Mallinckrodt Pharma IP Trading D.A.C.Inventors: Abraham Bout, Joseph Grimbergen, Jacob Koopman
-
Patent number: 10556055Abstract: An improved method for separating whole blood into components and collecting a desired blood component. The method allows a desired blood component to be subjected to centrifugal forces within a separator for prolonged periods of time, yielding a cleaner cut and higher yield of the desired blood component. Whole blood is drawn from a source and pumped into a separator, the undesired blood components are removed from the separator at rates so as to build up the desired blood component in the separator. The desired blood component is only removed after a predetermined amount of the desired blood component has built up in the separator. It is preferred that the desired blood component be buffy coat and that the method be used to perform photopheresis treatments. In another aspect, the invention is a method of performing a full photopheresis treatment to treat diseases in a reduced time, preferably less than about 70 minutes, and more preferably less than about 45 minutes.Type: GrantFiled: April 19, 2017Date of Patent: February 11, 2020Assignee: Mallinckrodt Hospital Products IP LimitedInventor: Dennis Briggs
-
Patent number: 10556082Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.Type: GrantFiled: January 23, 2017Date of Patent: February 11, 2020Assignee: Mallinckrodt Hospital Products IP LimitedInventors: Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
-
Patent number: 10556086Abstract: Methods of administering therapeutic gases containing high concentrations of nitric oxide, particularly concentrations above 2,000 ppm. The therapeutic gas may be administered at a certain dosing rate, such as less than 166 micrograms of nitric oxide per second. Also, methods of administering a therapeutic gas containing nitric oxide to a patient, wherein a dose of nitric oxide is administered from a portable device that includes a delivery system and a mini-cylinder. Methods can also include intermittent administration of nitric oxide pulses.Type: GrantFiled: March 14, 2013Date of Patent: February 11, 2020Assignee: Mallinckrodt Hospital IP LimitedInventors: Brahm Goldstein, Douglas Stuart Greene
-
Patent number: 10548920Abstract: Described are methods and systems for delivering a pharmaceutical gas to a patient. The methods and systems provide varying quantities of pharmaceutical gas delivered to the patient in two or more breaths based on the monitored respiratory rate or changes in the patient's respiratory rate.Type: GrantFiled: May 27, 2016Date of Patent: February 4, 2020Assignee: Mallinckrodt Hospital Products IP LimitedInventors: Frederick J. Montgomery, Duncan P. Bathe
-
Patent number: 10543334Abstract: A trap bowl is provided to accumulate liquid droplets from a filter, as a liquid content. The trap bowl includes a transparent vertical prism. The transparent vertical prism includes a face that forms a vertical transparent surface facing against a content of the section. The face can provide a first angle of total reflection when content of the section is a type of gas, and a second angle of total reflection when the content of the section is the liquid content. A light source may emit a light beam incident on the face at an angle of incidence. The angle of incidence results in reflection of the light beam, striking the light receiver, when the face has the first angle of total reflection, and results in refraction of the light beam, missing the light receiver, when the face has the second angle of total reflection.Type: GrantFiled: March 16, 2017Date of Patent: January 28, 2020Assignee: Mallinckrodt Hospital Products IP LimitedInventor: Scott I. Biba
-
Patent number: 10543325Abstract: Therapy gas delivery systems that provide run-time-to-empty information to a user of the system and methods for administering therapeutic gas to a patient. The therapeutic gas delivery system may include a gas pressure sensor attachable to a therapeutic gas source that communicates therapeutic gas pressure data to a therapeutic gas delivery system controller, a gas temperature sensor positioned to measure gas temperature in the therapeutic gas source that communicates therapeutic gas temperature data to the therapeutic gas delivery system controller, at least one flow controller that communicates therapeutic gas flow rate data to the therapeutic gas delivery system controller, at least one flow sensor that communicates flow rate data to the therapeutic gas delivery system controller, and at least one display that communicates run-time-to-empty to a user of the therapeutic gas delivery system.Type: GrantFiled: May 11, 2015Date of Patent: January 28, 2020Assignee: Mallinckrodt Hospital Products IP LimitedInventors: Jaron M. Acker, John C. Falligant, Jeff Milsap, Robin Roehl, Jeffrey Schmidt, Craig R. Tolmie
-
Patent number: 10537697Abstract: A method and system for generating and delivering nitric oxide directly to a patient. A reaction chamber is provided that is located at or in close proximity to the patient and reactants within the reaction chamber react together to produce a predetermined amount of nitric oxide. The reaction is controlled by metering at least one of the reactants into the reaction chamber to generate a predetermined quantity of nitric oxide as required by the patient. The reactants can include a nitrite salt, such as sodium nitrite, and a reductant such as ascorbic acid, maleic acid or a mixture thereof. By generating and delivering the nitric oxide directly to the patient in close proximity thereto, the formation of NO2 is minimized. One or both of the reactants may be in liquid form.Type: GrantFiled: January 27, 2016Date of Patent: January 21, 2020Assignee: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITEDInventors: Frederick Montgomery, Duncan Bathe
-
Patent number: 10533024Abstract: Embodiments describe methods of synthesizing metal mesoporphyrin compounds. In embodiments, a metal mesoporphyrin compound may be formed by hemin transmetallation and subsequent hydrogenation of the tin protoporphyrin IX to form a metal mesoporphyrin. In other embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a protoporphyrin methyl ester from hemin and converting the protoporphyrin methyl ester intermediate to a metal mesoporphyrin compound through metal insertion and hydrogenation. In other embodiments, a metal mesoporphyrin compound may be formed from hemin by a hydrogen-free hydrogenation method to form a mesoporphyrin IX intermediate followed by metal insertion and hydrogenation. In embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a mesoporphyrin IX dihydrochloride intermediate compound and converting the mesoporphyrin IX intermediate to a metal mesoporphyrin compound through metal insertion.Type: GrantFiled: September 7, 2018Date of Patent: January 14, 2020Assignee: MALLINCKRODT HOSPTIAL PRODUCTS IP LIMITEDInventors: Christopher P. Boucher, David Roe
-
Patent number: 10525226Abstract: The principles and embodiments of the present invention relate to methods and systems for safely providing NO to a recipient for inhalation therapy. There are many potential safety issues that may arise from using a reactor cartridge that converts NO2 to NO, including exhaustion of consumable reactants of the cartridge reactor. Accordingly, various embodiments of the present invention provide systems and methods of determining the remaining useful life of a NO2-to-NO reactor cartridge and/or a break-through of NO2, and providing an indication of the remaining useful life and/or break-through.Type: GrantFiled: May 14, 2015Date of Patent: January 7, 2020Assignee: Mallinckrodt Hospital Products IP LimitedInventors: Jaron Acker, Muhammad Asif, Craig Flanagan, Douglas Alan Greene, Sarah Jayne Ridley, Frank Kenneth Schweighardt, Lien-Lung Sheu
-
Patent number: 10512741Abstract: The present invention provides clinical decision support that can be used with non-portable and portable systems when delivering and/or monitoring delivery of a therapeutic gas comprising nitric oxide to a patient. Further, clinical decision support can be used with non-portable and portable systems during delivery and/or monitoring of delivery of therapeutic gas when nebulized drugs may and/or may not be being delivered to a patient (e.g., when nebulizers are delivered upstream in the inspiratory limb of the breathing circuit, into a breathing gas delivery system, etc.).Type: GrantFiled: September 13, 2013Date of Patent: December 24, 2019Assignee: Mallinckrodt Hospital Products IP LimitedInventors: Jaron Acker, Craig R. Tolmie
-
Patent number: 10486126Abstract: Compositions comprising at least 99.99% gaseous carbon monoxide, as well as pressurized cylinders containing such compositions. The compositions can have a Fe(CO)5 content less than 1 ppb, a Ni(CO)4 content less than 10 ppb, a water moisture content less than 5 ppm, and, a CO2 content less than 2 ppm. Gaseous carbon monoxide purities of 99.998% and 99.999% are achieved by removing residual air from the gaseous carbon monoxide.Type: GrantFiled: February 13, 2017Date of Patent: November 26, 2019Assignee: Mallinckrodt Hospital Products IP LimitedInventors: Tammer Mosa, Gerard T. Taylor